Quantitative proteomic analysis to decipher the differential apoptotic response of bortezomib‐treated APL cells before and after retinoic acid differentiation reveals involvement of protein toxicity mechanisms

The ubiquitin‐proteasome system allows the targeted degradation of proteins and plays a critical role in the regulation of many cellular processes. Proteasome inhibition is a recent antitumor therapeutic strategy and bortezomib was the first proteasome inhibitor approved for clinical use. In this study, we used the NB4 cell line to investigate the effects of bortezomib toward acute promyelocytic leukemia cells before and after retinoic acid‐induced differentiation. We showed that apoptosis level after bortezomib treatment is higher in NB4 cells than in differentiated NB4 cells. To compare early protein variations upon bortezomib treatment in both NB4 cell populations, we performed a quantitative proteomic analysis based on iTRAQ peptide labeling followed by data analysis with in‐house developed scripts. This strategy revealed the regulation of 14 proteins principally involved in protein stress response and apoptosis in NB4 cells after proteasome inhibition. Altogether, our results suggest that the differential level of apoptosis induced by bortezomib treatment in both NB4 cell populations could result from distinct protein toxicity level.

[1]  Knut Reinert,et al.  PPINGUIN: Peptide Profiling Guided Identification of Proteins improves quantitation of iTRAQ ratios , 2012, BMC Bioinformatics.

[2]  K. Akashi,et al.  Advances in therapies for acute promyelocytic leukemia , 2011, Cancer science.

[3]  M. Priault,et al.  ATRA-induced upregulation of Beclin 1 prolongs the life span of differentiated acute promyelocytic leukemia cells , 2011, Autophagy.

[4]  Sebastian A. Wagner,et al.  A Proteome-wide, Quantitative Survey of In Vivo Ubiquitylation Sites Reveals Widespread Regulatory Roles* , 2011, Molecular & Cellular Proteomics.

[5]  L. Kay,et al.  Novel proteasome inhibitors to overcome bortezomib resistance. , 2011, Journal of the National Cancer Institute.

[6]  X. Chen,et al.  Proteomics analysis of starved cells revealed Annexin A1 as an important regulator of autophagic degradation. , 2011, Biochemical and biophysical research communications.

[7]  D. Ron,et al.  Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress , 2011, Nature Cell Biology.

[8]  A. Tomoda,et al.  Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress. , 2011, International journal of oncology.

[9]  Andrei V. Gudkov,et al.  Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib , 2011, Oncotarget.

[10]  A. Laporte,et al.  Evidence for a second messenger function of dUTP during Bax mediated apoptosis of yeast and mammalian cells. , 2011, Biochimica et biophysica acta.

[11]  M. Bjørås,et al.  Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. , 2010, Blood.

[12]  Jun Yu,et al.  Proteasome inhibition: a new therapeutic strategy to cancer treatment. , 2010, Cancer letters.

[13]  D. Rubinsztein,et al.  Plasma membrane contributes to the formation of pre-autophagosomal structures , 2010, Nature Cell Biology.

[14]  Jun Yu,et al.  Macroautophagy modulates cellular response to proteasome inhibitors in cancer therapy. , 2010, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[15]  R. Mazroui,et al.  The chemotherapeutic agent bortezomib induces the formation of stress granules , 2010, Cancer Cell International.

[16]  B. Monsarrat,et al.  Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status. , 2010, Leukemia research.

[17]  M. Ferrarini,et al.  Bortezomib induces autophagic death in proliferating human endothelial cells. , 2010, Experimental cell research.

[18]  Rune Matthiesen,et al.  Virtual Expert Mass Spectrometrist: iTRAQ tool for database‐dependent search, quantitation and result storage , 2010, Proteomics.

[19]  L. Dick,et al.  Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. , 2010, Drug discovery today.

[20]  R. Parker,et al.  Eukaryotic stress granules: the ins and outs of translation. , 2009, Molecular cell.

[21]  Silke Meiners,et al.  Comprehensive proteomic and transcriptomic analysis reveals early induction of a protective anti‐oxidative stress response by low‐dose proteasome inhibition , 2009, Proteomics.

[22]  Christoph H Borchers,et al.  A comparison of MS/MS‐based, stable‐isotope‐labeled, quantitation performance on ESI‐quadrupole TOF and MALDI‐TOF/TOF mass spectrometers , 2009, Proteomics.

[23]  A. Kimchi,et al.  Life and death partners: apoptosis, autophagy and the cross-talk between them , 2009, Cell Death and Differentiation.

[24]  Daniela Hoeller,et al.  Targeting the ubiquitin system in cancer therapy , 2009, Nature.

[25]  A. Rosenwald,et al.  2‐D PAGE‐based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma , 2009, Electrophoresis.

[26]  Pedro Navarro,et al.  A refined method to calculate false discovery rates for peptide identification using decoy databases. , 2009, Journal of proteome research.

[27]  C. Koh,et al.  Apoptotic histone modification inhibits nuclear transport by regulating RCC1 , 2009, Nature Cell Biology.

[28]  D. McConkey,et al.  Mechanisms of proteasome inhibitor action and resistance in cancer. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[29]  A. Buchberger,et al.  UBX domain proteins: major regulators of the AAA ATPase Cdc48/p97 , 2008, Cellular and Molecular Life Sciences.

[30]  E. Colado,et al.  The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype , 2008, Haematologica.

[31]  R. Kaufman,et al.  The endoplasmic reticulum and the unfolded protein response. , 2007, Seminars in cell & developmental biology.

[32]  C. Peschle,et al.  M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib‐mediated apoptosis , 2007, British journal of haematology.

[33]  Odile Burlet-Schiltz,et al.  Mascot File Parsing and Quantification (MFPaQ), a New Software to Parse, Validate, and Quantify Proteomics Data Generated by ICAT and SILAC Mass Spectrometric Analyses , 2007, Molecular & Cellular Proteomics.

[34]  Lei Zhang,et al.  Proteomic changes of PC12 cells treated with proteasomal inhibitor PSI , 2007, Brain Research.

[35]  Shazib Pervaiz,et al.  Annexin 1: the new face of an old molecule , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  J. Leonard,et al.  Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Wen-Lian Hsu,et al.  Multi-Q: a fully automated tool for multiplexed protein quantitation. , 2006, Journal of proteome research.

[38]  L. Boise,et al.  Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. , 2006, Blood.

[39]  E. Ferrando-May.  Nucleocytoplasmic transport in apoptosis , 2005, Cell Death and Differentiation.

[40]  S. Schreiber,et al.  Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Charles Auffray,et al.  Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[42]  E. Bennett,et al.  Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. , 2005, Molecular cell.

[43]  R. Kaufman,et al.  The mammalian unfolded protein response. , 2003, Annual review of biochemistry.

[44]  K. Williams,et al.  Proteome and transcriptome analysis of retinoic acid-induced differentiation of human acute promyelocytic leukemia cells, NB4. , 2004, Journal of proteome research.

[45]  David A. Williams,et al.  Hematopoietic Cell Regulation by Rac1 and Rac2 Guanosine Triphosphatases , 2003, Science.

[46]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[47]  K. Chébli,et al.  The RasGAP-associated endoribonuclease G3BP assembles stress granules , 2003, The Journal of cell biology.

[48]  T. Libermann,et al.  Molecular sequelae of proteasome inhibition in human multiple myeloma cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[49]  E. Sztul,et al.  Hassles with Taking Out the Garbage: Aggravating Aggresomes , 2002, Traffic.

[50]  P. Elliott,et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.

[51]  R. Kopito,et al.  Aggresomes, inclusion bodies and protein aggregation. , 2000, Trends in cell biology.

[52]  Jay X. Tang,et al.  Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. , 1997, Science.

[53]  H. Drexler.  Activation of the cell death program by inhibition of proteasome function. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[54]  M. Taimi,et al.  Growth, differentiation, and death of retinoic acid-treated human acute promyelocytic leukemia NB4 cells. , 1997, Experimental cell research.

[55]  R Berger,et al.  NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). , 1991, Blood.

[56]  Najman,et al.  NB 4 , a Maturation Inducible Cell Line With t ( 15 ; 17 ) Marker Isolated From a Human Acute Promyelocytic Leukemia ( M 3 ) , 2022 .